Lupin Strengthens U.S. Pipeline with Key USFDA Tentative Approval

has received tentative approval from the U.S. Food and Drug Administration for its generic Sugammadex Injection, marking a strategic step in expanding its U.S. generics portfolio. The approval covers two strengths 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) in single-dose vials and the drug has been deemed bioequivalent to Bridion, a widely used reference product. Clinically, the injection is used to reverse the effects of neuromuscular blockers such as rocuronium bromide and vecuronium bromide in surgical procedures, targeting both adult and pediatric patients aged 2 years and above. Importantly, a tentative approval indicates that while the product meets all regulatory requirements, commercial launch in the U.S. will be subject to patent or exclusivity expiry. From a financial standpoint, Lupin continues to show strong momentum, reporting a 37.46% YoY rise in net profit to ₹1,175.55 crore and a 24.26% increase in revenue to ₹7,167.52 crore in Q3FY26, reflecting improving operational performance alongside pipeline expansion. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.